AST-OPC1 Clinical Study for Spinal Cord Injury Patients
Synopsis: Asterias Biotherapeutics AST-OPC1 treatment for spinal cord injury patients shown to help paralyzed patients regain function in arms and hands.1
Author: Asterias Biotherapeutics Contact: asteriasbio.com
Published: 2016-09-14
Main Digest
Asterias Biotherapeutics, based in Fremont, California, announced today positive interim efficacy data in the Company's ongoing Phase 1/2a clinical study in complete cervical spinal cord injury (loss of both motor function and sensation below the neck) patients.
While early in the study, with only 4 of the 5 patients having reached 90 days after dosing, all patients who received 10 million AST-OPC1 cells have shown at least one motor level of improvement (regaining some function in their arms) while 2 of 5 patients achieved two motor levels of improvement (regaining some function in their arms, hands and fingers) on at least one side of their body. Researchers initially thought that results would take 6-12 months to see. The next phase of the study - starting this fall - will utilize an even higher dose of AST-OPC1 (20 million cells).
Kris Boesen of Bakersfield, California, is shown lifting weights. Boesen, who was paralyzed from the neck down following a car accident in March 2016, now has use of his arms and hands following treatment with AST-OPC1, an investigational stem cell treatment developed by Asterias Biotherapeutics.
Oligodendrocyte Progenitor Cells (or OPC's) are a type of cell that is normally present in your brain and in your spinal cord throughout your life. These OPCs mature into a cell type called oligodendrocytes which help form the myelin (the insulation) around the nerve fibers in your brain and your spinal cord that allow nerve impulses to be conducted between your brain and spinal cord and ultimately to other parts of your body. AST-OPC1 is designed to help repair the myelin that has been damaged because of an injury to the spinal cord, and deliver additional benefits to spinal cord functioning as well. By implanting AST-OPC1 cells, the hope is that the signal from the brain that travels through the nerves of the spinal column can be restored (even partially) to allow for movement and sensation in the body.
Each year in the U.S. more than 17,000 people suffer a severe, debilitating spinal cord injury. Lifetime healthcare costs for these patients can often approach $5 million. The ability for a person to regain use of their arms, hands and fingers can dramatically improve their quality of life and ability to function independently.
The study is being conducted at six centers in the U.S.
- The Medical College of Wisconsin in Milwaukee
- Shepherd Medical Center in Atlanta
- Rancho Los Amigos/University of Southern California (USC) in Los Angeles
- Stanford University/Santa Clara Valley Medical Center in California
- Rush University Medical Center in Chicago
- Indiana University in Indianapolis
Additional information can be found at www.clinicaltrials.gov using Identifier NCT02302157, and at the SCiStar Study Website (www.scistar-study.com).
The SCiStar study is funded in part by a $14.3 million grant from the California Institute for Regenerative Medicine (CIRM).
For more information on Asterias, please visit www.asteriasbio.com
Related Clinical Trials Documents
Full List of Clinical Trials Publications Full List of Disabled World News UpdatesRecent Disability News and Updates
Disclaimer: Disabled World is strictly a news and information website provided for general informational purpose only and does not constitute medical advice. Materials presented are in no way meant to be a substitute for professional medical care by a qualified practitioner, nor should they be construed as such. Please report outdated or inaccurate information to us.
Disclosure: Disabled World is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com. Any 3rd party offering or advertising on disabled-world.com does not constitute endorsement by Disabled World. View our Advertising Policy for further information.